ASX CODE: PYC

Phylogica ASX PYC human cell penetrating peptide blinding eye disease

Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding...

Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery...
Read more
Phylogica ASX PYC study results Cell Penetrating Peptide CPP platform

Phylogica obtains successful time-course study results for flagship CPP platform

Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially...
Read more
Phylogica ASX PYC peptide vaccine T-Cell expansion results in vivo

Phylogica reports positive peptide vaccine T-Cell expansion results in vivo

Perth-based biotechnology company Phylogica (ASX: PYC) has announced a successful round of in vivo results in the evaluation of its cell-penetrating peptide (CPP) vaccine...
Read more
Phylogica ASX PYC Cre deliver drugs cells biotech biology

Purposeful cell targeting delivers commercial spoils for Phylogica

Biotech company Phylogica (ASX: PYC) has announced it has developed a new recombination enzyme, Cre, thereby supplementing its ongoing research into a proprietary in...
Read more
Phylogica ASX PYC peptide technology cancer vaccine

Phylogica’s peptide technology effective in development of cancer vaccine

Phylogica (ASX: PYC) has praised the effectiveness of its Functional Penetrating Peptide (FPP) technology to stimulate an immune response and extend cancer survival rates...
Read more

RECENT POSTS

STOCK SUMMARY

INVESTOR TOOLS

HOT TOPICS

TRENDING POSTS

Small Caps ASX Australian stock market
Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
Copyright 2019 Small Caps. All rights reserved.